Apixaban
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NonValvular Atrial Fibrillation
Conditions
NonValvular Atrial Fibrillation
Trial Timeline
Jul 10, 2013 → Sep 29, 2017
NCT ID
NCT01885598About Apixaban
Apixaban is a pre-clinical stage product being developed by Bristol Myers Squibb for NonValvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT01885598. Target conditions include NonValvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05187286 | Pre-clinical | Active |
| NCT03594045 | Phase 2 | Terminated |
| NCT02958969 | Approved | Completed |
| NCT03456648 | Phase 2 | Completed |
| NCT02714855 | Pre-clinical | Completed |
| NCT02345343 | Pre-clinical | Completed |
| NCT01885585 | Pre-clinical | Completed |
| NCT02153424 | Pre-clinical | Withdrawn |
| NCT02101112 | Phase 1 | Completed |
| NCT01884350 | Approved | Completed |
| NCT01885598 | Pre-clinical | Completed |
| NCT00252005 | Phase 2 | Completed |
Competing Products
6 competing products in NonValvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837 | AstraZeneca | Phase 2 | 52 |
| AZD0837 + VKA INR 2-3 | AstraZeneca | Phase 2 | 52 |
| Certoparin | Novartis | Phase 3 | 77 |
| Eliquis | Pfizer | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Pre-clinical | 20 |
| Rivaroxaban 20 MG + Warfarin | Bayer | Approved | 82 |